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Résumé en
anglais
Existing antifungal agents are still confronted to activities limited to specific fungal
species and to the development of resistance. Several improvements are possible
either by tackling and overcoming resistance or exacerbating the activity of existing
antifungal agents. In Candida glabrata, azole resistance is almost exclusively
mediated by ABC transporters (including C. glabrata CDR1 [CgCDR1] and CgCDR2)
via gain-of-function mutations in the transcriptional activator CgPDR1 or by
mitochondrial dysfunctions. We also observed that azole resistance was correlating
with increasing virulence and fitness of C. glabrata in animal models of infection.
This observation motivated the re-exploitation of ABC transporter inhibitors as a
possible therapeutic intervention to decrease not only the development of azole
resistance but also to interfere with the virulence of C. glabrata. Milbemycins are
known ABC transporter inhibitors, and here we used commercially available
milbemycin A3/A4 oxim derivatives to verify this effect. As expected, the derivatives
were inhibiting C. glabrata efflux with the highest activity for A3 oxim below 1 μg/ml.
More surprising was that oxim derivatives had intrinsic fungicidal activity above 3.2
μg/ml, thus highlighting effects additional to the efflux inhibition. Similar values were
obtained with C. albicans. Our data show that the fungicidal activity could be related
to reactive oxygen species formation in these species. Transcriptional analysis
performed both in C. glabrata and C. albicans exposed to A3 oxim highlighted a core
of commonly regulated genes involved in stress responses, including genes involved
in oxidoreductive processes, protein ubiquitination, and vesicle trafficking, as well as
mitogen-activated protein kinases. However, the transcript profiles contained also
species-specific signatures. Following these observations, experimental treatments of
invasive infections were performed in mice treated with the commercial A3/A4 oxim
preparation alone or in combination with fluconazole. Tissue burden analysis
revealed that oxims on their own were able to decrease fungal burdens in both
Candida species. In azole-resistant isolates, oxims acted synergistically in vivo with
fluconazole to reduce fungal burden to levels of azole-susceptible isolates. In
conclusion, we show here the potential of milbemycins not only as drug efflux
inhibitors but also as effective fungal growth inhibitors in C. glabrata and C.
albicans.
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